Endo Pharmaceuticals Press Release (02/16/12)
BioDelivery Sciences International (BDSI) has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance of BDSI's patent application that, once formally granted, will extend the exclusivity of the BioErodible Muco Adhesive (BEMA) drug delivery technology for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone from 2020 to 2027. As a part of BDSI's recently signed BEMA Buprenorphine licensing and development agreement with Endo Pharmaceuticals, BDSI is entitled to a milestone payment in the amount of $15 million upon the final granting of this patent.

Read the complete article